The DYNAMO Trial: IPI-145 for Refractory Indolent Non-Hodgkin Lymphoma

Video

Julian Adams, PhD, president, Research and Development, Infinity Pharmaceuticals, discusses the rationale for a phase II trial looking at IPI-145 for the treatment of patients with refractory indolent non-Hodgkin lymphoma.

Clinical Pearls

Julian Adams, PhD, president, Research and Development, Infinity Pharmaceuticals, discusses the rationale for a phase II trial looking at IPI-145 for the treatment of patients with refractory indolent non-Hodgkin lymphoma. This trial, labeled DYNAMO, was presented at the 2014 ASCO Annual Meeting.

  • In the course of a phase I investigation of IPI-145, patients with indolent lymphoma were enrolled.
  • The overall response rate of this group was 73%. The complete response rate was 20%.
  • These results were compelling enough to enroll a single-arm study of 120 patients with refractory indolent non-Hodgkin lymphoma. The trial is ongoing.
Related Videos
John Mascarenhas, MD, an expert on myelofibrosis
John Mascarenhas, MD, an expert on myelofibrosis
John Mascarenhas, MD, an expert on myelofibrosis
John Mascarenhas, MD, an expert on myelofibrosis
John Mascarenhas, MD, an expert on myelofibrosis
John Mascarenhas, MD, an expert on myelofibrosis
John Mascarenhas, MD, an expert on myelofibrosis
Related Content